Impact of TP53 Genomic Alterations in Large B-Cell Lymphoma Treated With CD19-Chimeric Antigen Receptor T-Cell Therapy.

Roni Shouval Ana Alarcon Tomas Joshua Alexander Fein Jessica R Flynn Ettai MarkovitsShimrit MayerAishat Olaide AfuyeAnna AlperovichTheodora AnagnostouMichal J BesserConnie Lee BatleviParastoo B DahiSean M Devlin Warren B Fingrut Sergio A Giralt Richard J LinGal MarkelGilles Andre SallesCraig S SauterMichael ScordoGunjan L Shah Nishi Shah Ruth Scherz-ShouvalMarcel van den BrinkMiguel-Ángel Perales Maria Lia Palomba

Published in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2021)

TP53 is a potent tumor-intrinsic biomarker that can inform risk stratification and clinical trial design in patients with LBCL treated with CD19-CAR-T. The role of TP53 should be further validated in independent cohorts.

Keyphrases

clinical trial
nk cells
diffuse large b cell lymphoma
copy number
open label
newly diagnosed
randomized controlled trial
phase ii
anti inflammatory
bone marrow
gene expression